Search hospitals > Arkansas > Jonesboro
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Claim this profileJonesboro, Arkansas 72401
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
116 reported clinical trials
20 medical researchers
Summary
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro is a medical facility located in Jonesboro, Arkansas. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro is involved with conducting 116 clinical trials across 258 conditions. There are 20 research doctors associated with this hospital, such as Philip E. Lammers, Raymond U. Osarogiagbon, Stephen W. Behrman, and Donald S. Gravenor.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage II
Stage I
Stage IV
Top PIs
Philip E. LammersBaptist Memorial Hospital and Cancer Center-Memphis4 years of reported clinical research
Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
35 drugs studied
Raymond U. OsarogiagbonBaptist Memorial Hospital and Cancer Center-Memphis5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
27 drugs studied
Stephen W. BehrmanBaptist Memorial Hospital and Cancer Center-Memphis4 years of reported clinical research
Studies Pancreatic Cancer
Studies Cancer
7 reported clinical trials
20 drugs studied
Donald S. GravenorBaptist Memorial Hospital and Cancer Center-Oxford7 years of reported clinical research
Studies Cancer
Studies Tumors
6 reported clinical trials
34 drugs studied
Clinical Trials running at NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Pancreatic Cancer
Pancreatic Carcinoma
Gallbladder Cancer
Colorectal Cancer
Squamous Cell Carcinoma
Fallopian Tube Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro?
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro is a medical facility located in Jonesboro, Arkansas. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro is involved with conducting 116 clinical trials across 258 conditions. There are 20 research doctors associated with this hospital, such as Philip E. Lammers, Raymond U. Osarogiagbon, Stephen W. Behrman, and Donald S. Gravenor.